Resources

Home / Resources

Tips and Tricks for Automated MS Data Analysis
Roundtable 4 Notes: Mass Spec 2021
Deep Dive into HCPs and Polysorbate/Product Degradation
Roundtable 3 Notes: Mass Spec 2021
Multi-Attribute Method (MAM) in Development vs. MAM in QC
Roundtable 2 Notes: Mass Spec 2021
Qualification and Validation of MS Methods 2021
Roundtable 1 Notes: Mass Spec 2021
Why and How to Move New Analytical Technologies from R&D to GMP
Roundtable 9 Notes: AT Europe 2020
Big Data - How Are Analytical Teams Addressing This, and Automation in Biopharmaceutical Development- an Answer or the Answer?
Roundtable 8 Notes: AT Europe 2020
Physicochemical Methods to Replace Traditional Bioassays
Roundtable 7 Notes: AT Europe 2020
NMR Opportunities and Challenges
Roundtable 6 Notes: AT Europe 2020
Phase-relevant Protein Characterisation
Roundtable 5 Notes: AT Europe 2020
Strategies for Defining Clinically Relevant Specifications
Roundtable 4 Notes: AT Europe 2020
Spectroscopic Characterisation of Biopharmaceuticals
Roundtable 3 Notes: AT Europe 2020
Implementing the Analytical Method Lifecycle Approach (ICH Q14/Revision of ICH Q2)
Roundtable 2 Notes: AT Europe 2020
CMC Strategy Forum Japan 2021 Presenter Media Kit
Presenter Media Kit
CMC Strategy Forum Japan 2021 Attendee Media Kit
Attendee Media Kit
Life Cycle Approach for Specifications
CMC Summary Paper: CMC Strategy Forum Europe 2007
CE Data Processing - Success Stories and Needed Improvements
Roundtable 8 Notes: CE Pharm 2021
Role CE in Real Time Release and Sample Prep Automation
Roundtable 7 Notes: CE Pharm 2021
Dips, Peaks, and pI Shifts: Mitigating Pharmalyte Lot Variability Impacts on cIEF Profiles
Roundtable 6 Notes: CE Pharm 2021
CE/MS: Successes and Challenges in Biopharmaceutical Development
Roundtable 5 Notes: CE Pharm 2021
New CE Frontiers - AAV, Vaccine Applications, Opportunities and Limitations for CE in DNA/RNA Applications
Roundtable 4 Notes: CE Pharm 2021